TW EN

scroll

Go Top

Overview

TCTC

1. Pharmacotherapy of mental disorders has been developed for more than half century; however, the efficacy has been limited. Due to diversity of mental disorders, large and high-quality clinical trials are crucial to develop novel treatment strategies for mental disorders. Therefore, we set up a coordinative clinical-trial consortium “Taiwan Clinical Trial Consortium for Mental Disorders (CMD)”.

2. PI, Dr. Hsien-Yuan Lane led an investigator initiated multi-center trial, demonstrating that a first-in-the-world therapy could be used to treat the hardest-to-treat schizophrenia, and the study was published in 2018 at Biological Psychiatry (IF: 13.382). The editor prepared press release and the article was selected for cover image of the journal. Moreover, Dr. Lane and the Co-PI, Dr. Chieh-Hsin Lin were selected to exhibit their innovative technology in 2021 Future Tech Awards, highlighting their distinguished contribution to the novel diagnosis of Alzheimer’s disease.

3. Currently, our consortium integrates eight hospitals to conduct multi-center trials together. Moreover, our consortium successfully finished an international trial transferred from clinical trial center in our hospital. Our consortium will continue to cooperate with it to promote clinical trials.

Strengths

TCTC

1. Schizophrenia

2. Dementia

3. Depression

4. Bipolar disorder

5. Addiction

Major Achievements

TCTC

Aspect of international cooperation:

Our consortium is conducting three international multi-center clinical trials.

1. Cooperate with Merck (America) for a phase II trial related to the development of new drug for schizophrenia. (NCT: 04624243)

2. Cooperate with Sumitomo Dainippon Pharma (Japan) for a phase II/III trial related to the development of new drug for schizophrenia. (NCT: 04825860)

3. Cooperate with Boehringer Ingelheim (Germany) for a phase III trial related to the development of new drug for schizophrenia. (NCT: 04860830)

Aspect of industry/academia/research:

Our consortium is conducting two local multi-center clinical trials.

1. Cooperate with Excelsior Pharma for a phase II trial related to the development of new drug for schizophrenia.

2. Cooperate with Excelsior Pharma for a phase II trial related to the development of new drug for dementia.

Aspect of society and others:

According to the information from World Health Organization, depression is one of three main diseases in the world that we need to concern highly. Our consortium continues to conduct clinical trials related to depression. For example, using Transcranial Magnetic Stimulation (TMS) to treat depression. TMS was allowed to treat treatment-resistant depression in Taiwan. Our Co-PI, Dr. Cheng-Ta Li has obtained the 16th Tien Te Lee Biomedical Award, highlighting his distinguished contribution on treating the treatment-resistant depression using TMS. Moreover, he continues to conduct trials related to depression. He has published an article at Chronic Stress (IF: 3.00). His achievements are expected to have important beneficial effect for our society.

Milestone of our consortium:

1. PI, Dr. Hsien-Yuan Lane and the Co-PI, Dr. Chieh-Hsin Lin was selected to exhibit their innovative technology in 2021 Future Tech Awards, highlighting their distinguished contribution to the novel diagnosis of Alzheimer’s disease.

2. Dr. Hsien-Yuan Lane and the Co-PI, Dr. Ruu-Fen Tzang obtained the 18th National Innovation Award, highlighting their distinguished contribution in using sodium benzoate as a novel therapy for anti-NMDAR encephalitis.

Members

TCTC

China Medical University Hospital

National Taiwan University Hospital

Taipei Veterans General Hospital

National Cheng Kung University Hospital

National Cheng Kung University Hospital

Chang Gung Memorial Hospital, Linkou

Hualien Tzu Chi Hospital

Kai-Syuan Psychiatric Hospital

Chang Gung Memorial Hospital, Keelung

Contact Information

c-IRB

Hsien-Yuan Lane

Email:hylane@gmail.com

TEL:04 22052121 ext #1074 #1855